Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Digital Realty Trust | Eli Lilly and Company | Dell Technologies | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The FY2026 10-K describes advantages that are real but shallow, and a revenue mix that is diluting them. It names them as 'our end-to-end solutions portfolio, go-to-market capabilities, supply chain, and global services' and calls the direct sales channel 'a significant competitive advantage', while conceding it faces 'ongoing product and price competition in all areas of our business from both branded and generic competitors' and, on components, that 'any disruption that may occur because of our dependence on single- or limited-source vendors would not disproportionately disadvantage us relative to our competitors' - i.e. no differentiated supply position. The filing's own margin table shows where the franchise actually earns: total gross margin fell from 23.8% of net revenue in Fiscal 2024 to 22.2% in Fiscal 2025 to 20.0% in Fiscal 2026, and inside that, product gross margin fell 17.5% to 15.8% to 13.7% while services gross margin rose 40.8% to 41.4% to 44.8%. Narrow rather than none, because the high-margin services and storage core is intact and its margin rate improved; narrow rather than wide, because the line that is growing carries a 13.7% product gross margin and the filing attributes the whole decline to it. |
| Moat type | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | cost scale The filing locates the advantage in scale of distribution and supply, not in proprietary rights. It states 'Our world-class supply chain operates at significant scale', describes a direct sales force plus a partner network that produced 'approximately 40% of our net revenue' in Fiscal 2026, and lists supply chain and global services among its competitive advantages. The IP alternative is ruled out in the same document: with 25,859 granted patents held at January 30, 2026, Dell still says 'we are not substantially dependent on any single patent or group of related patents.' |
| Leadership | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader The 10-K's only positioning claim is the unquantified 'Dell Technologies is a leader in the global technology industry'; it names no competitor and gives no share anywhere. The band therefore rests on disclosed absolute scale - ISG net revenue of 60,826m and CSG net revenue of 50,984m in Fiscal 2026, operations in over 170 countries - set against the filing's own admission that hyperscale Infrastructure-as-a-Service buyers 'often buy their infrastructure directly from original design manufacturers', which caps how much of the market Dell can lead at all. |
| Pricing power | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak The filing describes price-taking and its own tables confirm it. It reports 'ongoing product and price competition in all areas of our business from both branded and generic competitors' and says 'We closely monitor market pricing, including the effect of foreign exchange rate movements, in an effort to provide the best value for our customers.' Total gross margin fell from 23.8% of net revenue in Fiscal 2024 to 22.2% in Fiscal 2025 to 20.0% in Fiscal 2026, with product gross margin down to 13.7%; CSG operating margin fell three straight years (7.6%, 6.1%, 5.6% of segment revenue); and non-GAAP operating income as a percentage of net revenue 'decreased 10 basis points to 8.8%' even as revenue grew 19%. Consolidated operating margin did rise 70 basis points to 7.2%, but the filing credits a lower operating expense rate for that, not price. |
| Summary | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | The AI-server line is enormous and it is not a moat - the FY2026 10-K says so in its own margin bridge. AI-optimized servers net revenue went 1,873m in Fiscal 2024 to 9,286m in Fiscal 2025 to 24,683m in Fiscal 2026 (+396% then +166%), lifting total ISG revenue to 60,826m (+40%). Over the same year ISG operating income as a percentage of segment revenue fell 110 basis points to 11.7% 'due to a decline in gross margin rate that outpaced the decline in operating expense rate. Gross margin rate decreased primarily as the result of a shift in mix towards our AI-optimized servers offerings', and the Fiscal 2027 outlook repeats the expectation of 'margin rate pressure resulting from a continuing shift in mix towards our AI-optimized servers offerings'. The cleanest test of pass-through is the filing's product-versus-services split: product net revenue grew 27% to 90,405m at a 13.7% gross margin (down from 15.8% and 17.5%), while services net revenue fell 4% to 23,133m at a 44.8% gross margin. The AI boom arrived entirely as thin product revenue and did not pull the profitable services book along with it. What Dell adds is described plainly as integration: it uses contract manufacturers, buys components from suppliers and 'subsequently sell[s] those components to the manufacturer', and its own 'manufacturing process consists of assembly, software installation, functional testing, and quality control'. The bypass is named too: 'We also face competition from non-traditional IT companies, including large Infrastructure-as-a-Service providers, that often buy their infrastructure directly from original design manufacturers. Competitive pressures could increase if customers choose to move existing workloads to these providers.' What survives as a moat is the part an ODM cannot sell an enterprise: a direct sales force and account teams, a global service and support footprint whose gross margin rate is still rising, storage that held revenue within 3% of flat through the whole mix shift, and Dell Payment Solutions financing that produces multiyear recurring arrangements. |
| Chain position | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Integrator between accelerator and component suppliers and enterprise or sovereign buyers: the 10-K says Dell purchases components from suppliers, sells them on to contract manufacturers, and performs 'assembly, software installation, functional testing, and quality control', then reaches customers through a direct sales force and a partner network that generated about 40% of Fiscal 2026 net revenue. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |